Umlaut.bio develops first-in-biology small molecules focusing on tRNAs that protect signalling transduction mRNAs from degradation. Addressing this previously undrugged fundamental biochemical principle  could be able to selectively prevent the growth of cancer as well as  proinflammatory cells.

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2024
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in